Meme Kanseri ve Menopozal Semptomlara Yaklaşım
References
Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021 Nov 1;41(11):1183–94. doi:10.1002/cac2.12207 PubMed PMID: 34399040.
Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy. Springer Nature; 2025. doi:10.1038/s41392-024-02108-4 PubMed PMID: 39966355.
Garrido Oyarzún MF, Castelo-Branco C. Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical? Gynecological Endocrinology. Taylor and Francis Ltd; 2017. p. 10–5. doi:10.1080/09513590.2016.1247798 PubMed PMID: 27898259.
Cohen PA, Brennan A, Marino JL, Saunders CM, Hickey M. Managing menopausal symptoms after breast cancer – A multidisciplinary approach. Maturitas. Elsevier Ireland Ltd; 2017. p. 4–7. doi:10.1016/j.maturitas.2017.04.013 PubMed PMID: 28473176.
Eden J. ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer. Eur J Endocrinol. 2016 Mar;174(3):R71-7. doi:10.1530/EJE-15-0814 PubMed PMID: 26466611.
Loibl S, Lintermans A, Dieudonné AS, Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas. 2011. p. 148–54. doi:10.1016/j.maturitas.2010.11.013 PubMed PMID: 21185135.
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. The Lancet. 2004 Feb;363(9407):453–5. doi:10.1016/S0140-6736(04)15493-7
Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 1;100(7):475–82. doi:10.1093/jnci/djn058 PubMed PMID: 18364505.
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst. 2005 Apr 6;97(7):533–5. doi:10.1093/jnci/dji071 PubMed PMID: 15812079.
Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013 Jan;49(1):52–9. doi:10.1016/j.ejca.2012.07.003 PubMed PMID: 22892060.
Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncology. 2009. Report.
Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric. Taylor and Francis Ltd; 2019. p. 572–8. doi:10.1080/13697137.2019.1646718 PubMed PMID: 31433675.
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. The Lancet. 2015 Oct 3;386(10001):1341–52. doi:10.1016/S0140-6736(15)61074-1 PubMed PMID: 26211827.
